Discovery could lead to higher immunotherapy response rates for bladder cancer patients

(The Mount Sinai Hospital / Mount Sinai School of Medicine) Mount Sinai researchers have discovered that a particular type of cell present in bladder cancer may be the reason why so many patients do not respond to the groundbreaking class of drugs known as PD-1 and PD-L1 immune checkpoint inhibitors, which enable the immune system to attack tumors.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news